1. IGF2BP2 is significantly elevated in both gastric cancer tissues and cells.
2. Silencing of IGF2BP2 suppresses inflammation, proliferation, migration and invasion, yet promotes cell apoptosis in vitro and in vivo.
3. IGF2BP2 increases the expression of IGF1R by identifying m6A methylation modification sites in IGF1R mRNA, thus activating RhoA-ROCK pathway.
The article is generally reliable and trustworthy as it provides a detailed description of the research conducted to investigate the role of IGF2BP2 in gastric cancer progression. The authors have provided evidence for their claims through experiments such as qRT-PCR, western blotting, CCK-8 assay, ELISA, flow cytometry analysis, Transwell assay and tumor formation in nude mice. Furthermore, they have also verified the binding relationship between IGF1R and IGF2BP2 using RIP and RNA pull down assays.
However, there are some potential biases that should be noted when assessing the trustworthiness of this article. Firstly, the authors do not provide any information on possible risks associated with silencing of IGF2BP2 or activation of RhoA-ROCK pathway which could lead to an incomplete understanding of the implications of their findings. Secondly, there is a lack of exploration into counterarguments which could provide a more balanced view on the topic being discussed. Finally, there is no mention of any promotional content which could be seen as partiality towards certain conclusions or results obtained from the experiments conducted by the authors.